Skip to main content

Table 1 Baseline patient characteristics of different degrees of ST-segment resolution

From: ST-segment resolution as a marker for severe myocardial fibrosis in ST-segment elevation myocardial infarction

Variables

All (n = 42)

ST-segment resolution ≥ 40.15%

ST-segment resolution < 40.15%

P

(n = 26)

(n = 16)

Male/female (n)

30/12

20/6

10/6

0.483

Age (years)

62.0 (54.5–70.0)

60.5 (52.8–70.3)

63.5 (59.5–69.5)

0.534

BMI (Kg/m2)

24.2 (23.0–25.6)

24.3 (23.4–25.8)

24.2 (21.9–24.7)

0.378

Smoking history (No, %)

27 (64.3%)

17 (65.4%)

10 (62.5%)

0.850

HP history (no, %)

27 (64.3%)

14 (53.8%)

13 (81.2%)

0.072

DM history (no, %)

16 (38.1%)

12 (46.2%)

4 (25.0%)

0.170

Hyperlipidemia (no, %)

21 (50.0%)

13 (50.0%)

8 (8.0%)

1.000

Pain to balloon time (h)

5.79 (3.67–7.60)

4.33 (3.50–6.23)

7.04 (5.81–8.40) *

0.001

Killip classification (no, %)

   

0.757

 Killip I

29 (74.4%)

19 (79.2%)

10 (66.67%)

 

 Killip II

10 (25.6%)

5 (20.8%)

5 (33.33%)

 

Number of DES (no, %)

   

0.142

 One

34 (87.2%)

22 (95.7%)

12 (75.0%)

 

 Two

3 (7.7%)

1 (4.3%)

2 (12.5%)

 

 Three

2 (5.1%)

0 (0.0%)

2 (12.5%)

 

Culprit artery, (No, %)

   

0.171

 LAD

18 (42.9%)

8 (30.8%)

10 (62.5%)

 

 LCC

11 (26.2%)

8 (30.8%)

3 (18.8%)

 

 RCA

13 (31.0%)

10 (38.5%)

3 (18.8%)

 

WBC count (109/L)

9.85 (8.28–12.06)

10.09 (8.28–12.06)

9.72 (8.03–14.12)

0.875

RBC count (1012/L)

4.44 (3.91–4.82)

4.44 (4.14–4.86)

4.45 (3.71–4.72)

0.449

Hb (g/L)

139.0 (125.0–151.0)

139.0 (128.0–151.0)

135.5 (113.3–150.8)

0.449

PLT (109/L)

198.0 (163.0–238.0)

195.0 (160.0–213.0)

212.5 (175.0–282.3)

0.204

HbA1c (%)

6.0 (5.7–7.2)

6.1 (5.7–8.2)

5.9 (5.7–6.4)

0.188

ALT (U/L)

42.0 (35.0–56.0)

41.0 (35.0–56.0)

46.0 (36.0–53.5)

0.689

AST (U/L)

126.0 (52.0–209.0)

75.0 (35.0–153.0)

185.5 (101.1–237.3)

0.015

Cr (umol/L)

73.0 (60.0–81.0)

73.0 (59.0–81.0)

71.5 (60.3–83.3)

0.954

BNP (pg/ml)

57.9 (7.9–245.0)

11.7 (5.0–62.7)

227.5 (80.0–381.2) *

< 0.001

Peak troponin-T (ng/ml)

11.6 (6.2–19.3)

7.0 (3.8–14.0)

18.6 (12.2–24.9) *

< 0.001

LVIDd (mm)

49.0 ± 3.3

49.0 ± 3.3

49.5 ± 3.2

0.298

LVEF (%)

53.5 (48.0–58.25)

57.0 (53.5–61.0)

47.5 (44.3–50.0) *

< 0.001

Scar thickness

70.0 (55.0–80.0)

59.0 (50.0–70.0)

81.0 (80.0–85.0) *

< 0.001

Transmural myocardial scar (no, %)

17 (40.5%)

2 (7.7%)

15 (93.8%)*

< 0.001

Scar size

17.35 (12.23–20.30)

12.90 (11.13–19.40)

20.00 (18.13–23.63) *

0.001

IIa/IIIb inhibitor (no, %)

17 (43.6%)

11 (47.8%)

6 (37.5%)

0.522

Aspirin (no, %)

39 (100.0%)

23 (100.0%)

16 (100.0%)

1.000

Ticagrelor/clopidogrel (no, %)

39 (100.0%)

23 (100.0%)

16 (100.0%)

1.000

Statins (no, %)

39 (100.0%)

23 (100.0%)

16 (100.0%)

1.000

β-blocker (no, %)

31 (79.5%)

17 (73.9%)

14 (87.5%)

0.432

ACEI/ARB

24 (61.5%)

14 (60.9%)

10 (62.5%)

0.918

Nitrates (no, %)

38 (97.4%)

22 (95.7%)

16 (100.0%)

1.000

Diuretics (no, %)

16 (41.0%)

6 (26.1%)

10 (62.5%)

0.023

CCU (hours)

48.0 (39.0–62.0)

47.0 (38.0–58.0)

52.5 (44.0–82.8)

0.123

  1. Data are data are presented as mean ± SD, median (interquartile ranges), or number (%)
  2. STEMI ST-segment elevation myocardial infarction, BMI body mass index, HP hypertension, DM diabetes mellitus, DES drug eluting stents, LAD left anterior descending coronary artery, LCC left circumflex coronary artery, RCA right coronary artery, LVIDD left ventricular diastolic diameter, LVEF left ventricular ejection fraction, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blocker, CCU coronary heart disease care unit
  3. *P < 0.05 comparing with ST-segment resolution ≥ 40% group
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us